NDA 201699 · Cubist Pharms LLC
Dificid
Fidaxomicin · Oral · Macrolide Antibacterial
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: May 28, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
May 27, 2011
Approved uses
3
Original approval plus efficacy supplements
Registered trials
33
13 Phase 3, 3 recruiting
FAERS reports
2,417
1,442 serious, 258 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 16, 2024.
DIFICID is a macrolide antibacterial indicated in adult and pediatric patients 6 months of age and older for the treatment of C. difficile -associated diarrhea. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile . ( 1.2 ) 1.1 Clostridioides difficile -Associated Diarrhea DIFICID ® is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile -associated diarrhea (CDAD). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile . When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Fidaxomicin is an antibacterial drug [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 24, 2020 Supplement 12 · Efficacy · priority review OrphanLetterLabel
- Feb 24, 2015 Supplement 9 · Efficacy · priority review Letter
- May 27, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewPediatric Written Request
1 products under this application
- DIFICID · FIDAXOMICIN 200MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fidaxomicin" as an intervention, any sponsor and status, largest first.
- A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01241552 · 1,452 participants · Start Oct 10, 2011 · Primary completion Dec 9, 2014
Drug: MK-3415; MK-6072 and 3 more · For: Clostridium Difficile Infection
- A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01513239 · 1,203 participants · Start Feb 1, 2012 · Primary completion May 22, 2015
Drug: MK-6072; MK-3415A and 2 more · For: Clostridium Difficile Infection
- Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)Pivotal-lookingCompleted
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00314951 · 629 participants · Start May 2, 2006 · Primary completion Jul 23, 2008
Drug: Fidaxomicin; Vancomycin and 1 more · For: Clostridium Infections; Diarrhea
- Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)Pivotal-lookingCompleted
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT01691248 · 611 participants · Start Oct 10, 2012 · Primary completion Mar 18, 2015
Drug: fidaxomicin; Placebo · For: Clostridium Difficile-Associated Diarrhea (CDAD)
- PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)Pivotal-lookingCompleted
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT00468728 · 535 participants · Start Oct 4, 2006 · Primary completion Dec 11, 2009
Drug: PAR-101/OPT-80; Vancomycin · For: Clostridium Infections; Diarrhea
Sites: Gadsden, Alabama; Phoenix, Arizona; Hot Springs, Arkansas · 116 sites in all
- Vancomycin Taper to Prevent Recurrent Clostridioides DifficilePivotal-lookingRecruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT07328971 · 500 participants (planned) · Start May 1, 2026 · Primary completion Jul 1, 2031
Drug: Fidaxomicin; Vancomycin capsule · For: Clostridia Difficile Colitis
Sites: Edmonton, Canada; Montreal, Canada
- STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile InfectionPivotal-lookingNot yet recruiting
Medical University of WarsawAcademic, hospital or other
NCT07120490 · 424 participants (planned) · Start Oct 2025 · Primary completion Mar 31, 2027
Drug: Fidaxomicin; Vancomycin (VAN) treatment · For: Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence; Fecal Microbiota Transplantation (FMT) and 3 more
- A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older PopulationPivotal-lookingCompleted
Astellas Pharma Europe Ltd.Astellas (ALPMY)
NCT02254967 · 364 participants · Start Nov 6, 2014 · Primary completion Mar 27, 2016
Drug: Fidaxomicin; Vancomycin · For: Clostridium Difficile
Sites: Graz, Austria; Linz, Austria; Salzburg, Austria · 109 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- clostridium difficile infection484
- drug ineffective419
- diarrhoea354
- disease recurrence179
- clostridium difficile colitis162
- off label use135
- nausea125
- treatment failure120
- abdominal pain88
- no adverse event86
- pyrexia78
- vomiting73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 15 |
| 2012 | 36 |
| 2013 | 276 |
| 2014 | 122 |
| 2015 | 162 |
| 2016 | 121 |
| 2017 | 99 |
| 2018 | 147 |
| 2019 | 195 |
| 2020 | 192 |
| 2021 | 156 |
| 2022 | 170 |
| 2023 | 160 |
| 2024 | 206 |
| 2025 | 220 |
| 2026 | 140 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dificid (Fidaxomicin)
2024 spending
$154M
Beneficiaries
26,020
34,589 claims
Per beneficiary
$5,909
$245.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $47,384,305 |
| 2021 | $67,952,402 |
| 2022 | $103,081,747 |
| 2023 | $127,162,103 |
| 2024 | $153,755,014 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Comparative Study
- SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
Feuerstadt P, Louie TJ, Lashner B, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis.
Zhao Z, Wu Y, Geng X, et al. · Medicine (Baltimore) 2024 · Systematic Review, Meta-Analysis
- Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
Guery B, Menichetti F, Anttila VJ, et al. · Lancet Infect Dis 2018 · Clinical Trial, Phase III, Clinical Trial, Phase IV
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA, Crook DW, Esposito R, et al. · Lancet Infect Dis 2012 · Clinical Trial, Phase III, Comparative Study
- An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
Rao K, Zhao Q, Bell J, et al. · Clin Infect Dis 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Cubist Pharms LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.